A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis MRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Latest Information Update: 16 Sep 2026
At a glance
- Drugs GBP 560 (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors SK Bioscience
Most Recent Events
- 11 Sep 2026 Status changed from recruiting to completed.
- 19 Mar 2025 Status changed from not yet recruiting to recruiting.
- 25 Feb 2025 According to the SK Bioscience Media Release, the company announced commencement of this trial.